The slowdown in the domestic ultrasound industry trimmedDiasonics Ultrasound revenue last year, although the company reducedits net loss compared to 1992. For the year ended December, Milpitas, CA-based Diasonics reportednet sales of $195.4 million,
The slowdown in the domestic ultrasound industry trimmedDiasonics Ultrasound revenue last year, although the company reducedits net loss compared to 1992.
For the year ended December, Milpitas, CA-based Diasonics reportednet sales of $195.4 million, compared to $205.1 million in 1992.The net loss for the year was $8.5 million, compared to a $22million net loss reported in 1992.
Diasonics reported a break-even fourth quarter, a significantimprovement over the $5.5 million loss reported for the same periodlast year. Net sales for the quarter were $57.2 million, comparedto $62.3 million in the same quarter last year.
In cardiology, revenues increased 20% over last year, primarilydue to European sales of the company's Vingmed CFM cardiologyproduct line, according to president and CEO Bruce N. Moore.
Diasonics last year split its ultrasound business into a separatecompany, apart from former x-ray subsidiary OEC of Salt Lake City(SCAN 2/24/93).
ADAC Laboratories reported that sales of its Genesys Vertexadjustable dual-head gamma camera contributed to a 28% increasein revenue for the first quarter (end-January). Price competitionhas put a strain on profit margins, however, according to thevendor.
ADAC reported revenues for the quarter of $46.5 million, comparedto $36.3 million in the same period a year ago. Income for thequarter was $5.3 million, compared to income of $4.1 million forthe first quarter of 1993, as adjusted for a one-for-three stocksplit in March 1993.
ADAC also reported that it is pleased with the progress ofthe first week of hearings in the patent infringement case filedagainst the firm by competitor Elscint. Elscint's motion for preliminaryinjunction against ADAC is being heard in the U.S. District Courtof Maryland. A trial in the case has been set for October.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.